Axsome Therapeutics (AXSM) total liabilities

Total liabilities · fiscal 2025
$601.51M

Axsome Therapeutics (AXSM) had total liabilities of $601.51M at the end of fiscal 2025 (December 31, 2025). That is 17.6% higher than the $511.48M of fiscal 2024. Figures as of 19 Nov 2026, 00:41 UTC, from the company's filings with the SEC and Yahoo Finance.

Key facts

Total liabilities, fiscal 2025
$601.51M
Change on fiscal 2024
+17.6%
Growth, 5 years
+52.7% a year
Growth, 10 years
+72.1% a year
Highest on record
$601.51Mfiscal 2025
Lowest on record
$2.63Mfiscal 2015
Fiscal years on record
112015–2025

Figures as of . Older fiscal years come from the company's filings with the SEC, recent ones from Yahoo Finance. Amounts are in USD. Figures, not advice.

Axsome Therapeutics total liabilities, in more detail

Over the five fiscal years to 2025 total liabilities grew at a compound 52.7% a year; over ten years the rate was 72.1% a year. Across the 11 fiscal years on record (2015–2025), the highest was $601.51M in fiscal 2025 and the lowest $2.63M in fiscal 2015.

History · 11 fiscal years

Total liabilities by fiscal year

Axsome Therapeutics total liabilities, year by year

Axsome Therapeutics (AXSM) total liabilities by fiscal year
Fiscal yearTotal liabilitiesChangeYear ended
2025$601.51M 17.6% up
2024$511.48M 28.8% up
2023$397.26M 79.0% up
2022$221.92M 207.6% up
2021$72.15M 0.3% down
2020$72.34M 73.0% up
2019$41.83M 189.6% up
2018$14.44M 23.3% down
2017$18.84M 13.2% up
2016$16.64M 532.3% up
2015$2.63M—

Change is on the fiscal year before; a dash means that year is not on record or the earlier figure was not positive. A dash anywhere else means the figure was not reported or cannot be computed — it is never filled in.

Method

How it is calculated

Total liabilities is everything the company owes at the fiscal year-end — borrowings, payables, deferred revenue, lease and pension obligations and the rest.

How to read it

It is broader than debt: read it against total assets, and remember that for a bank or an insurer customer deposits and policy reserves are liabilities too.

Total liabilities at health care companies of similar size

Total liabilities of Axsome Therapeutics and comparable companies
CompanyTotal liabilitiesFiscal year
Immunovant IMVT$104.42M2026
Axsome Therapeutics AXSM$601.51M2025

The latest fiscal year on record for each company, in the currency it reports in. Fiscal years end at different times of year.

More on AXSM

Axsome Therapeutics, figure by figure

Axsome Therapeutics (AXSM) overview: price, valuation and scorecardAll health care companies by market value

Axsome Therapeutics total liabilities: questions and answers

How large are Axsome Therapeutics's total liabilities?

Axsome Therapeutics (AXSM) had total liabilities of $601.51M at the end of fiscal 2025 (December 31, 2025). That is 17.6% higher than the $511.48M of fiscal 2024.

What is the growth rate of Axsome Therapeutics's total liabilities?

Over the five fiscal years to 2025 total liabilities grew at a compound 52.7% a year; over ten years the rate was 72.1% a year.

What are the highest and lowest total liabilities figures on record for Axsome Therapeutics?

Across the 11 fiscal years on record (2015–2025), the highest was $601.51M in fiscal 2025 and the lowest $2.63M in fiscal 2015.

How is Axsome Therapeutics's total liabilities calculated?

Total liabilities is everything the company owes at the fiscal year-end — borrowings, payables, deferred revenue, lease and pension obligations and the rest. For Axsome Therapeutics it is on record here for 11 fiscal years, 2015 to 2025.

Fiscal years are named for the calendar year they end in.

Cite this page

Funkfolio, “Axsome Therapeutics (AXSM) total liabilities”, data as of 19 November 2026. https://funkfolio.com/stock/AXSM/total-liabilities

Underlying data: the company's filings with the SEC and Yahoo Finance.